About this trial
This trial looks at how well surgery works for patients with high risk retroperitoneal sarcoma. It compares surgery alone to surgery after chemotherapy given before the operation. The main goal is to see if adding chemotherapy helps patients live longer without the cancer coming back.
The trial's ID number is NCT04031677. This is a Phase 3 trial, which means it is looking at how well the treatment works and how safe it is. It is regulated by the FDA and aims to include about 250 participants.
Who can join
Adults aged 18 and older can join this trial. It is open to both men and women with specific types of high risk sarcoma. The trial team will confirm if each person meets the eligibility requirements.
Conditions
Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will be placed into two groups by chance. One group will have surgery alone. The other group will receive chemotherapy before their surgery. Everyone will receive care to help them recover.
Where
This trial is running at 109 locations in the United States. 97 of them are currently recruiting.
Allegheny General Hospital
Pittsburgh, Pennsylvania
Allegheny Valley Hospital
Natrona Heights, Pennsylvania
Carilion Roanoke Memorial Hospital
Roanoke, Virginia
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina
City of Hope Comprehensive Cancer Center
Duarte, California
Cooper Hospital University Medical Center
Camden, New Jersey
Dana-Farber/Harvard Cancer Center
Boston, Massachusetts
Duke University Medical Center
Durham, North Carolina
The first 8 of 109 sites are listed here. The registry record has the full list.